Philippines Medical Device Approval Process: What the FDA Does With Your File, Stage by Stage

Philippines Medical Device Approval Process: What Happens Inside the FDA After You File

Once a device file is submitted, it moves through four gates inside the Philippine FDA: intake and completeness screening, technical evaluation by an assigned reviewer, one or more deficiency rounds, then a decision. Nothing else happens in between. Almost every complaint about how long approval takes traces back to one of those four gates — usually the third.

This guide is written from the regulator's side of the desk. It is not a filing checklist: for the applicant-side sequence — who may hold the licence, what documents to assemble, how the risk classes work — start with the medical device registration guide for the Philippines. What follows is the other half of the picture, the half nobody sends you a letter about: what the reviewer is actually doing with your dossier while your commercial team is asking for an approval date.

Three structural facts explain most of the frustration:

• Evaluation is sequential, not parallel. Your file is not being worked on continuously. It sits in a queue, gets picked up, gets a decision or a deficiency letter, and — if deficiencies are issued — goes back into a queue after you respond.
• The establishment layer gates the product layer. No valid company License to Operate (LTO), no product application. Applicants who start the product clock in their heads on the day they finish the technical file are usually months out of step with reality.
• A deficiency round is a restart, not a pause. This is the single most misunderstood part of medical device approval in Philippines practice, and the reason honest timelines are always stated as ranges.

Every figure and requirement below is described as a mechanism, not a promise. Fees, processing targets and documentary requirements are set by FDA issuances that are revised periodically — always check the FDA's current circulars and fee schedule for the version in force on the day you file.

The Approval Process for Medical Devices in Philippines, Stage by Stage

The approval process for medical devices in Philippines filings runs in this order: establishment licence first, then product application, then screening, evaluation, deficiency rounds and decision — and only the last four are what people mean by "the review".

• Stage 0 — Establishment (LTO). The company that will import, distribute or manufacture must hold a valid LTO for that activity, tied to a declared and inspectable facility and a qualified technical person. It typically runs on its own multi-week to multi-month calendar and generally has to be in place before the product file is accepted. It is a common hidden cause of a "slow" approval that never actually started.
• Stage 1 — Submission and payment. The application is lodged through the FDA's electronic portal with the prescribed fees. Nothing is reviewed until payment is validated and the application is captured.
• Stage 2 — Intake / completeness screening. An administrative check that the mandatory documents are present, legible, current and internally consistent. This is a gate, not an evaluation, and it is where a large share of files bounce within the first days or weeks.
• Stage 3 — Technical evaluation. An evaluator at the FDA's device centre reads the dossier against the declared risk class and intended use. This is the stage whose length varies most, and it is driven by class, route and queue depth.
• Stage 4 — Deficiency / compliance letters. If anything is missing or unconvincing, the FDA issues a letter listing what it wants, with a response deadline stated in the letter. Your file leaves active review until you answer.
• Stage 5 — Decision. Approval issues as a CMDN certificate for notification-route devices or a CMDR / registration certificate for the registration route, with a validity term. Or the file is disapproved, or treated as abandoned if a deadline lapsed.
• Stage 6 — Post-market. Renewal before expiry, reporting of variations, and adverse event and recall obligations. Approval is a licence to keep complying, not a finish line.

Two of these stages are entirely in your control (0 and 1), one is shared (4), and only stages 2, 3 and 5 belong purely to the FDA. Companies that shorten their calendar do it by winning stages 0, 1 and 4 — not by chasing the reviewer.

Stage 2: Intake Screening — Where Files Die Before Anyone Reads the Science

Intake screening asks one question: is this file complete, current and internally consistent enough to be worth an evaluator's time? It is administrative, it is fast, and it is unforgiving — a dossier with excellent clinical data and an expired Certificate of Free Sale fails here without the data ever being opened.

What gets checked at this gate is boring and mechanical, which is exactly why it should never cost you a round:

• Applicant standing. Is there a valid LTO, is it valid for the activity claimed, and is the applicant on the product form the same legal entity as the licence holder? A mismatch between the licence holder, the authorisation letter and the application form is a classic bounce.
• Foreign document legalisation. Certificates of Free Sale, ISO 13485 certificates, CE certificates and manufacturer authorisation letters that originate abroad usually need notarisation plus apostille or consular authentication, and they must still be valid on the filing date. The legalisation queue in the country of origin should be the very first thing you start — see how apostille and authentication work for documents used in the Philippines.
• Scope consistency. Model names, catalogue numbers, sizes and configurations must match across the authorisation letter, the free-sale certificate, the labels and the application form. Any product that appears in one document and not another is a deficiency waiting to be written.
• Declared class and route. The class you declared has to be defensible from the stated intended use, and it has to match the route you filed under.
• Labels and instructions for use. Present, legible, in the required language, and consistent with the claims made everywhere else in the file.

The practical rule: nothing at this gate requires judgement, so nothing at this gate should ever be the reason your file comes back. Run a line-by-line consistency pass across every document in the pack before you submit — one person, one afternoon, comparing names and numbers cell by cell. It is the cheapest week you will ever buy back.

Stage 3: Technical Evaluation — What the Reviewer Is Actually Checking

The evaluator is not asking "is this a good device". They are asking whether the evidence in the file supports the specific claims on your label, for the specific risk class you declared, under the framework the Philippines applies. Everything else is noise.

For registration-route devices the dossier is normally structured on the ASEAN Common Submission Dossier Template (CSDT), and the reviewer works through it roughly in this order:

• Intended use versus classification. Read first, and the most consequential thing in the file. If the intended use implies a higher-risk claim than the class you declared, the whole submission is on the wrong track and no amount of downstream data rescues it.
• Device description and scope. What is in the box, what variants and accessories are covered, and whether related items have been grouped defensibly rather than bundled for convenience. Over-broad grouping is a frequent trigger for a letter asking you to split the application.
• Essential principles of safety and performance. A mapping exercise: for each applicable principle, which standard, test or rationale demonstrates conformity — and where in the file it sits. Vague cross-references and "see attached" without a page pointer generate questions.
• Verification and validation evidence. Electrical safety and EMC for powered devices, biocompatibility for patient-contacting materials, sterilisation validation and shelf-life for sterile products, software lifecycle evidence where software is a component, and analytical and clinical performance where the product is a diagnostic. For diagnostics specifically the evidence set is different enough to be worth reading separately — see IVD registration in the Philippines.
• Risk management. A real risk file, with hazards traced to controls and residual risk justified — not a template with the device name changed.
• Labelling and IFU consistency. Every claim on the label must be supported inside the dossier, and every specimen type, indication, population or shelf-life figure printed on the box must be traceable to a study or a standard.
• Manufacturing and quality system status. Site identity, quality certification, and whether the certificate actually covers the site and product range being filed.

The pattern behind nearly all technical deficiencies is the same: a claim that is stated somewhere and demonstrated nowhere. Before filing, take the label and the IFU, list every claim on them, and point each one at a page of evidence. Claims that cannot be pointed at are either deleted from the label or supported before submission. That one exercise removes the majority of avoidable rounds.

Stage 4: Deficiency Letters, and Why Each Round Restarts the Clock

A deficiency or compliance letter takes your file out of active review until you respond — so every round adds not just your response time but a fresh wait in the queue afterwards. This is the mechanism behind almost every timeline that blows out, and it is why nobody can honestly promise an approval date.

What actually happens on a deficiency round:

• The evaluator issues a letter listing what is missing or unconvincing, with a response deadline stated in the letter itself. Deadlines and any extension mechanism are set by FDA issuance and change over time — read the letter, diarise the date, and do not rely on what a colleague remembers from a previous filing.
• Your file stops being worked on. The reviewer moves to the next file.
• You respond. A complete, point-by-point response that answers every item in the order it was raised gets picked up faster than a partial one — and a partial response reliably earns a second letter.
• The response re-enters the queue. Depending on the queue at that moment, waiting to be picked up again can take comparable time to the original wait.
• Missing the deadline is the worst outcome available. Depending on the issuance in force, a lapsed deadline can mean disapproval or the application being treated as abandoned — meaning you re-file and re-pay rather than continue.

Two behaviours reliably multiply rounds. The first is answering only the easy items and promising the hard one "to follow" — that guarantees another cycle. The second is fixing the specific document the FDA named without fixing the same defect where it also appears elsewhere in the pack; the next reviewer finds it in the second location and writes another letter.

Second deficiency letter already, and the clock has restarted again? → dossier review before you re-file

The strategic point: a first-round-clean file and a three-round file follow the same rules and pay the same fees, but land in different quarters. Time spent on internal review before submission is bought back at a heavy multiple.

How Long Medical Device Approval in Philippines Takes, and What Sets the Range

Honest answer: notification-route (lower-risk) products are generally decided in a matter of weeks when the file is clean, while registration-route products commonly run several weeks to several months — and any deficiency round can push a file into the next band. Those are ranges, not commitments, and the FDA's own published processing targets are the reference point that matters.

Anyone quoting a single fixed number for the medical device approval process in Philippines filings is quoting a best case with the deficiency round silently deleted. The variables that actually set where you land:

• Route and risk class. The notification route for the lowest-risk class is a lighter review than a full registration for higher-risk devices, and the gap between them is large.
• Completeness on day one. The single biggest lever you control. A file that survives intake and needs no technical letter is in a different universe from one that needs two rounds.
• Number of deficiency rounds. Each one adds your response time plus a fresh queue wait.
• Queue depth at the device centre. Outside your control and genuinely variable across the year.
• Whether the LTO is already in hand. If not, the real calendar starts with the establishment licence — including facility readiness and the technical-person requirement — not with the product file.
• Legalisation lead time abroad. Apostille or consular authentication of manufacturer documents is often the longest single lead item and is entirely outside the FDA's process. Start it first.
• Scope of the application. A broad family with many variants and configurations takes longer to evaluate than a single well-defined product, and is more likely to attract a request to split.

How to plan against this without lying to your own commercial team: plan the licence and the legalisation as the critical path, budget for at least one deficiency round as the normal case rather than the bad case, and never promise a launch date that assumes a clean first pass. The rest of the import chain — appointing the party that will appear on the customs entry, and the release of the first consignment — should be sequenced behind the approval, not in parallel with an assumed date; see how the importer of record works in the Philippines.

Why Files Get Rejected, and Whether Anything Can Be Expedited

Outright disapproval is less common than a slow death by deficiency rounds, and the reasons cluster into a short, boringly predictable list. None of them are about the quality of the device.

• Wrong classification. A device filed a class too low relative to its intended use, or a diagnostic classified using general-device logic. Everything downstream inherits the error.
• Intended-use drift. The dossier, the label, the IFU and the free-sale certificate describe subtly different products or subtly different claims. Four documents, four stories.
• Unsupported claims. Something on the label — a population, an indication, a shelf life, a performance figure — that no page in the file demonstrates.
• Legalisation gaps. Expired free-sale certificate, unauthenticated foreign documents, or an authorisation letter that has lapsed or names an entity that is not the applicant.
• Applicant standing problems. No valid LTO, an LTO that does not cover the activity, or a mismatch between the licence holder and the applicant named on the product file.
• Scope mismatch. Models or catalogue numbers that do not reconcile across documents, or grouping that cannot be justified.
• Silent changes. A manufacturing site, formulation, configuration or label changed after filing and not reported. Found later, this is materially worse than a slow approval.
• Lapsed response deadlines. Administrative, entirely avoidable, and fatal to the application.

On expediting: there is no general paid fast lane for a routine device application. Priority handling exists in specific public-health circumstances — the emergency-use style pathways used during a declared health emergency are the obvious example — and those are policy instruments, not a service you buy. What genuinely shortens the calendar is unglamorous: start the legalisation before anything else, get the LTO moving in parallel with dossier preparation rather than after it, submit a file that survives intake untouched, and answer any deficiency letter completely and on the first attempt.

Treat any consultant who offers a guaranteed approval, a guaranteed date, or a way to "push" a file inside the agency as a warning sign about everything else they will do with your submission.

How the Decision Relates to the CMDN, CMDR, CPR and Your LTO

"Approval" is not one document. It is a company-level licence (the LTO) plus a product-level certificate — a CMDN for notification-route devices, a CMDR or registration certificate for the registration route — and the trade often calls the product certificate the CPR regardless of category.

• LTO — License to Operate. Licenses the company for a declared activity: importer, distributor or wholesaler, trader, manufacturer. Tied to an inspectable facility and a qualified technical person. It is the prerequisite: the licence holder is the applicant on every product file, so an LTO in someone else's name means the registration is in someone else's name too.
• CMDN — the notification route certificate. Issued for lower-risk devices on a lighter review. Faster, but not a waiver: the technical file still has to exist and still has to be produced on demand, and mis-declaring a class to reach this route is one of the more expensive mistakes available.
• CMDR / registration certificate — the registration route. Issued for higher-risk devices after a full technical evaluation, with a validity term.
• CPR — Certificate of Product Registration. The general term used across FDA-regulated categories, and the word most buyers, tenders and forwarders will use when they ask whether you are "registered". For how this establishment-then-product structure works across food, cosmetics and other categories, see the FDA product registration overview.

Three consequences worth internalising before you file:

• Whoever holds the LTO holds the registration. Filing through a local distributor's licence is the fastest way into the market and a completely legitimate route — but the certificate sits in their name, and moving it later is a re-filing, not an edit. Agree transfer, termination and data-handover terms before the first submission, not after the relationship sours.
• Approval has an expiry. Renewal is its own process with its own lead time, and letting a certificate lapse can push you back to a new application rather than a renewal.
• Approval is scoped. It covers the models, configurations and claims that were evaluated. New variants, a new manufacturing site, a reformulation or a label change are variations to be reported or filed — not things to do quietly and mention at renewal.

Summary and Disclaimer

The short version: the FDA screens for completeness, evaluates the evidence against your declared class and claims, writes to you when something is missing, and decides — and every round of that correspondence costs you a queue wait, not just a reply.

• The establishment licence gates the product file. Your real timeline starts there, not at dossier completion.
• Intake screening is administrative and should never cost you a round. Reconcile every name, number and date across every document before submitting.
• Technical deficiencies almost always mean a claim stated somewhere and demonstrated nowhere.
• A deficiency letter is a restart, not a pause. Budget for one; aim for none.
• Timelines are ranges driven by route, file quality and queue depth — plan launches against ranges, and never against a promised date.
• There is no general fast lane. File quality is the only lever that reliably moves the calendar.

This article is general information only and is not legal, regulatory or medical advice. Classification rules, dossier requirements, processing targets, response deadlines and fees for medical devices are set by Philippine FDA issuances that are amended from time to time, and outcomes are highly product-specific. Every requirement and timeline described here is subject to the FDA rules and fee schedule in force on the day you file — verify against the FDA's current circulars, and treat any promised approval date or guaranteed outcome as a claim nobody is in a position to make. If you want the file pressure-tested before the FDA sees it — class determination, claim-to-evidence mapping, legalisation sequencing and a realistic calendar — Yixing's product access team can tell you where the dossier will break first.